Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Summary

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

Timeline

Start

2025-10-27

Primary completion

2030-10

Completion

2031-10

Drugs

Indications